Please assess the completion status of the following clinical trial:

Trial Title: Paracetamol And Ibuprofen/Indomethacin in Closing Patent Ductus Arteriosus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Preterm infants (born before 37+0 gestation weeks) who are diagnosed to have a hemodynamically significant PDA and who, according to the decision of the attending clinician, need ibuprofen therapy, are eligible to this trial.~Exclusion Criteria:~* severe malformation or suspected chromosomal defect~* other very severe life-threatening disease (e.g. very severe birth asphyxia or persistent pulmonary hypertension, etc.)

- Gender: ALL
- Minimum Age: None
- Maximum Age: 4 Months
- Healthy Volunteers: f

Study Arms:
- Pedea 5mg/mL and Paracetamol 10mg/mL (Type: EXPERIMENTAL): Intravenous (IV) ibuprofen 5mg/mL q 24h for 3 days, dosages: 10mg/kg + 5mg/kg + 5mg/kg and IV paracetamol 10mg/mL for 3 days: loading dose 20mg/kg, following 7.5mg/kg q 6h (up to12 doses)
- Pedea 5mg/mL and 0.45 sodium chloride (Type: PLACEBO_COMPARATOR): IV ibuprofen 5mg/mL q 24h for 3 days, dosages: 10mg/kg + 5mg/kg + 5mg/kg and NaCl 0.45% for 3 days, the same amount in mL as would have been given IV paracetamol
- Indomethacin 25mg/mL and Paracetamol10mg/mL (Type: EXPERIMENTAL): Intravenous (IV) indometahcin 25mg/mL q 24h for 3 days, dosages: 0.2mg/kg + 0.1mg/kg + 0.1mg/kg and IV paracetamol 10mg/mL for 3 days: loading dose 20mg/kg, following 7.5mg/kg q 6h (up to12 doses)
- Indomethacin 25mg/mL and 0.45 sodium chloride (Type: PLACEBO_COMPARATOR): Intravenous (IV) indomethacin 25mg/mL q 24h for 3 days, dosages: 0.2mg/kg + 0.1mg/kg + 0.1mg/kg and NaCl 0.45% for 3 days, the same amount in mL as would have been given IV paracetamol

Based on this trial design, predict the completion outcome and termination type (if applicable).